Abstract
A new class of pharmaceutical molecules – synthetic vaccines, synthetic diagnostics and peptide drugs – are emerging based on recent advances of peptide libraries, supramolecular chemistry and rational design. The molecules of this growing class have exciting potential, not met by classical drugs based on small molecules or recombinant proteins.
This is a preview of subscription content, log in via an institution to check access.
References
Ruoslahti, E. and Piersbacher M. D., Arg-Gly-Asp: A versatile cell recognition signal, Cell, 44 (1986) 517–518.
Antoni, G., Presentini, R., Perin, F., Tagliabue, A., Ghiara, P., Censin, S., Volpini, G., Villa, L. and Boraschi, D., Short synthetic peptide fragment of human interleukin 1 with immunostimulatory but not inflammatory activity, J. Immunlogy, 137 (1986) 3202–3204.
Keane, A. M., Trayer, I. P., Levine, B. A., Zeugner, C. and Ruegg, J. C., Peptide mimitics of an actin site on myosin span two functional domains on actin, Nature, 344 (1990) 265–268.
Roland, J., Berezov, A., Greene, M. I., Murali, R., Piatier-Tonneau, D., Devaux, C. and Briant, L., The synthetic CD4 exocyclic CDR3.AME(82-89) inhibits NF-kappaB nuclear translocation, HIV-1 promoter activation, and viral gene expression, DNA Cell Biol., 18 (1999) 819–828.
Dennis, M. S., Quan, C. R. M. and Lazarus, R. A., Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa, Biochemistry, 40 (2001) 9513–9521.
Khan, N. A., Khan, A., Savelkoul, H. F and Benner, R., Inhibition of septic shock in mice by an oligopeptide from the beta-chain of human chorionic gonadotrophin hormone, Hum. Immunol., 63 (2001) 1–7.
Orning, L., Fischer, P. M., Hu, C. K., Agner, E., Engebretsen, M., Husbyn, M., Petersen, L. B., Orvim, U., Llinas, M. and Sakriassen, K. S., A cyclic peptapeptide derived from the second EGF-like domain of Factor VII is an inhibitor of tissue factor dependent coagulation thrombus formation, Thromb. Haemost., 87 (2002) 13–21.
Adessi, C., Frossard, M. J., Boissard, C., Fraga, S., Bieler, S., Ruckle, T., Vilbois, F., Robinson, S. M., Mutter, M., Banks, W. A. and Soto, C., Pharmacological profiles of peptide drug candidates for the treatment of Alzheimer's disease, J. Biol. Chem., 278 (2003) 13905–13911.
Betts, R., Weinsheimer, S., Blouse, G. E. and Anagli J., Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT, J. Biol. Chem., 278 (2003) 7800–7809.
Gomez, I., Miranda-Rios, J., Rudino-Pinera, E., Oltean, D. I., Gill, S. S., Bravo, A. and Soberon, M., Hydropathic complementarity determines interaction of epitope (869)HITDTNNK(876) in Manduca sexta Bt-R(1) receptor with loop 2 of domain II of Bacillus thuringiensis Cry1A toxins, J. Biol. Chem., 277 (2002) 30137–30143.
Tsumoto, K., Misawa, S., Ohba, Y., Ueno, T., Hayashi, H., Kasai, N., Watanabe, H., Asano, R. and Kumagai, I., Inhibition of hepatitis C virus NS3 protease by peptides derived from complementarity-determining regions (CDRs) of the monoclonal antibody 8D4: Tolerance of a CDR peptide to conformational changes of a target, FEBS Lett., 525 (2002) 77–82.
Monfardini, C., Canziani, G., Plugariu, C., Kieber Emmons, T., Godillot, A. P., Kwah, J., Bajgier, J., Chaiken, I. and Williams, W. V., Structure-based design of mimetics for granulocyte-macrophage colony stimulating factor (GM-CSF), Curr. Pharm. Des., 8 (2002) 2185–2199.
Wells, J. A., Hormone mimicry, Science, 273 (1996) 449–450.
Cwirla, S. E., Balasubramanian, P., Duffin, D. J., Wagstrom, C. R., Gates, C. M., Singer, S. C., Davis, A. M., Tansik, R. L., Mattheakis, L. C., Boytos, C. M., Schatz, P. J., Baccanari, D. P., Wrighton, N. C., Barrett, R. W. and Dower, W. J., Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine, Science, 276 (1997) 1696–91997.
Takasaki, W., Kajino, Y., Kajino, K., Murali, R. and Greene, M. I., Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor, Nat. Biotechnol., 15 (1997) 1266–1270.
Uings, I. J., Balasubramanian, P., McLoughlin, P. G., Yin, Q., Dash, L., Beresford, A., Kearney, S., Barrett, R. W., McKinnon, M. and England, B. P., Modified peptide antagonists of interleukin 5 exhibit extended in vivo persistence but restricted species specificity, Cytokine, 7 (2001) 10–9.
Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A. and Lowman, H. B., Stable 'zeta' peptides that act as potent antagonists of the high-affinity IgE receptor, PNAS, 99 (2002) 1303–1308.
James, T-20 and Trimiris, AIDS Treat News, 293 (1998) 1–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Meloen, R., Timmerman, P. & Langedijk, H. Bioactive peptides based on diversity libraries, supramolecular chemistry and rational design: A new class of peptide drugs. Introduction. Mol Divers 8, 57–59 (2004). https://doi.org/10.1023/B:MODI.0000025698.16766.11
Issue Date:
DOI: https://doi.org/10.1023/B:MODI.0000025698.16766.11